BIO vs PLUS · rev $2.58B vs P/E 17, rev $2.07B
BIO (BIO) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
BIO currently screens at market cap $0. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the BIO and PLUS stock pages for the full models.
Not investment advice.